ArticlePloS one2026
Association between results of component-resolved diagnostics and basophil activation in Hymenoptera venom allergy: A registry-based cross-sectional study in adults.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergy to Hymenoptera venom is one of the most frequent causes of anaphylaxis in adults. Conventional diagnostic approaches, including skin testing and measurement of allergen-specific IgE (sIgE) to venom extracts, do not always allow for precise identification of the culprit venom. This remains particularly challenging in patients with double-positive or inconclusive conventional test results, which may complicate the decision-making process regarding qualification for appropriate treatment. Component-resolved diagnostics (CRD) and the basophil activation test (BAT) may provide complementary information in such cases and aid in qualification for subcutaneous immunotherapy (SCIT).
methodsIn this retrospective registry-based cross-sectional study, 154 adults who had been evaluated for Hymenoptera venom allergy at the Military Institute of Medicine (Warsaw, Poland) between December 2023 and May 2025 were included. Patients were divided into three groups: not qualified for SCIT (n = 27), qualified for bee venom immunotherapy (n = 32), and qualified for wasp venom immunotherapy (n = 95). Serum sIgE to venom extracts and certain components (rApi m 1, m 2, m 3, m 5, m 10; rVes v 1, v 5) were measured. BAT was performed by flow cytometry assessing CD63 expression.
resultsModerate correlations were found between BAT results and sIgE to rApi m 1 (rho = 0.495; p < 0.001) and rVes v 5 (rho = 0.456; p < 0.001). No correlation was observed for rVes v 1, and negative correlations were noted between rApi m 1 and rVes v 5 in heterologous BAT responses. No statistically significant association was observed between the severity of previous sting reactions and BAT or sIgE parameters. However, due to limited subgroup sizes, these analyses were underpowered and the results should be interpreted as inconclusive.
conclusionsAmong the examined variables, the major components Api m 1 and Ves v 5 were the most strongly correlated with specific basophil activation in vitro. The combined use of CRD and BAT may support clinical assessment and facilitate decisions regarding immunotherapy qualification. Further prospective studies are warranted to assess the prognostic and clinical relevance of our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.